| Name | Title | Contact Details |
|---|
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.
Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.
HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.